Policy / Pricing SCOTUS won’t hear pharma’s IRA complaints PharmaphorumThe US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare’s drug pricing negotiation powers. Read full story Post navigation Previous: 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics AcceleratorNext: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026